Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of Efficacy and Safety of Semaglutide s.c. Once-weekly Versus Placebo in Subjects With Non-alcoholic Steatohepatitis and Compensated Liver Cirrhosis

NCT03987451 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03987451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03987451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of Efficacy and Safety of Semaglutide s.c. Once-weekly Versus Placebo in Subjects With Non-alcoholic Steatohepatitis and Compensated Liver Cirrhosis
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
June 18, 2019
Completion date
June 10, 2021
Enrollment
71 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic steatohepatitis